Abstract 1535P
Background
Ramucirumab (Ram) combined with docetaxel is an approved 2nd-line treatment in patients (pts) with squamous cell carcinoma (SCC) of the lung (REVEL study) and with paclitaxel for esophagogastric adenocarcinoma (RAINBOW study). In SCC of the oesophagus, nivolumab is currently the only evidence-based 2nd-line treatment option. This study evaluates the safety and efficacy of Ram plus paclitaxel.
Methods
This prospective, randomized, open-label, multicentre, phase II trial evaluated paclitaxel plus Ram (Ram 8 mg/kg d1, 15 and paclitaxel 80 mg/m2 d1, 8, 15) Arm A vs. paclitaxel alone (80 mg/m2 d1, 8, 15) Arm B, both q4w. Primary endpoint was overall survival rate at 6 months (mos) (OS@6), main secondary endpoints were OS, PFS, objective response rate (ORR) and safety.
Results
From 3/2019 to 4/2021, 21/186 planned pts were treated within the study protocol (Arm A 11 pts; Arm B 10 pts) in 9 German centres. Due to slow accrual, the study was terminated prematurely. Median age was 63y, 71% were male and 86% had relevant concomitant disease. Pts received a median of 9 and 10 cycles in Arms A and B, respectively. Median follow-up was 9 mos (0.7 – 32.4 mos). OS@6 in Arm A was 73% for Ram/paclitaxel and 50% for paclitaxel. However, the study design did not allow for statistical comparison of the arms. ORR (CR+PR 18% vs. 20%) and DCR (CR+PR+SD 55% vs. 60%) were in the same range, as well as median PFS (3.8 vs. 3.5 mos) and OS (12.1 vs. 9.2 mos) for Arms A and B, respectively. The most common treatment related adverse events (AEs) in Arm A were leucopoenia (55%), fatigue (27%) and peripheral sensory neuropathy (18%). Treatment related AEs ≥ grade 3 occurred in 27% in Arm A and 50% in Arm B. Serious AEs (SAEs) occurred in 36% and 50% in Arms A and B, respectively.
Conclusions
Ram and Paclitaxel shows an acceptable tolerability and numerically improved OS@6. Due to the small number of pts the current trial must be considered exploratory, and more data are needed in this indication.
Clinical trial identification
NCT03762564.
Editorial acknowledgement
Legal entity responsible for the study
Institut für Klinische Krebsforschung IKF am Krankenhaus Nordwest.
Funding
Lilly Deutschland GmbH.
Disclosure
T.O. Goetze: Other, Advisory Role: Lilly, MSD Oncology, Bayer, Servier, Roche, Novartis, Incyte, Foundation Medicine, Bristol Myers Squibb; Other, Speaker’s Bureau: Lilly; Financial Interests, Research Funding: Deutsche Forschungsgemeinschaft, Gemeinsamer Bundesausschuss, Deutsche Krebshilfe, Lilly, AstraZeneca, Incyte. T.J. Ettrich: Other, Advisory Role: Eisai, MSD Oncology, Bayer, Roche, Sanofi, Bristol Myers Squibb, Incyte, AstraZeneca, Merck, Pierre Fabre, Servier, Lilly, Ipsen, BMS GmbH & Co. KG, Daiichi Sankyo Europe GmbH; Financial Interests, Other, Travel, Accommodations, Expenses: Ipsen; Financial Interests, Research Funding: Baxalta/Shire. H. Schmalenberg: Other, Advisory Role: Lilly, Novartis, BMS GmbH & Co. KG, MSD, Merck. R.J.C. Mahlberg: Other, Advisory Role: AstraZeneca. G. Hapke: Financial Interests, Research Funding: MSD, Bristol Myers Squibb, Gilead Sciences, BioNTech. P.C. Thuss-Patience: Other, Advisory Role: Bristol Myers Squibb, Merck, Lilly, Novartis, Pfizer, Roche, AstraZeneca, Daiichi Sankyo, Astellas Pharma, MSD, Servier; Financial Interests, Research Funding: Merck/Pfizer. S. Al-Batran: Other, Advisory Role: Lilly, Bristol Myers Squibb, Merck Sharp & Dohme, MacroGenics, AstraZeneca, Daiichi Sankyo; Other, Speaker’s Bureau: Lilly, AIO GmbH, Bristol Myers Squibb, MCI Group; Financial Interests, Stocks or ownership: Institut für Klinische Krebsforschung GmbH, Immutep; Financial Interests, Research Funding: Celgene, Lilly, Medac, Hospira, Sanofi, German Cancer Aid, German Research Foundation, Federal Ministry of Education and Research, Roche, Vifor Pharma, Eurozyto, Immutep, Ipsen, Bristol Myers Squibb, Merck Sharp & Dohme, AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
1498P - HGF/MET pathway is associated with poor efficacy of Immune checkpoint inhibitors (ICIs) in advanced-stage NSCLC
Presenter: Assya Akli
Session: Poster session 21
1499P - Wnt5-ROR2 signalling mediated resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer
Presenter: Etienne Giroux-Leprieur
Session: Poster session 21
1500TiP - REFINE-Lung is a multicentre phase III study to determine the optimal frequency of pembrolizumab in non-small cell lung cancer utilising a novel multi-arm design
Presenter: Ehsan Ghorani
Session: Poster session 21
1502TiP - A phase I/IIa trial of ChAdOx1 and MVA vaccines against MAGE-A3 and NY-ESO-1
Presenter: Fiona Blackhall
Session: Poster session 21
1503TiP - A phase II study of cemiplimab plus BNT116 versus cemiplimab alone in first-line treatment of patients with advanced non-small cell lung cancer with PD-L1 expression ≥50%
Presenter: Mark Awad
Session: Poster session 21
1504TiP - HARMONi: Randomized, double-blind, multi-center, phase III clinical study of ivonescimab or placebo combined with pemetrexed and carboplatin in patients with EGFR-mutant locally advanced or metastatic non-squamous NSCLC who have progression following EGFR-TKI treatment
Presenter: WenFeng Fang
Session: Poster session 21
1505TiP - TROPION-Lung07: A phase III trial of datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy in advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) with PD-L1 expression
Presenter: Isamu Okamoto
Session: Poster session 21
1506TiP - A single-arm, phase II study of amivantamab (AMI), lazertinib (L) and pemetrexed (P) for first-line treatment of recurrent/metastatic non-small cell lung cancers (NSCLCS) with epidermal growth factor receptor mutations in Exons 19 or 21 (EGFR 19/21): AMIGO 1 (LACOG0821)
Presenter: William Nassib William Junior
Session: Poster session 21
1507TiP - Phase Ib multicenter study of trastuzumab deruxtecan (T-DXd) and immunotherapy with or without chemotherapy in first-line treatment of patients (pts) with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (OE): DESTINY-Lung03
Presenter: David Planchard
Session: Poster session 21